Innoviva (INVA) Cost of Revenue (2011 - 2026)
Innoviva's (INVA) quarterly Cost of Revenue came in at $15.6 million in Q1 2026, up 76.51% YoY from $8.8 million in Q1 2025, and down 65.38% on a QoQ basis from $45.1 million in Q3 2025.
Innoviva (INVA) Cost of Revenue (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 7 years of Cost of Revenue data on file, last reported at $15.6 million in Q1 2026.
- Quarterly Cost of Revenue rose 76.51% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.1 million (up 38.8% YoY) and the FY2025 annual result came in at $77.4 million, changed N/A from the prior year.
- Cost of Revenue fell to $15.6 million in Q1 2026, from $45.1 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $45.1 million in Q3 2025 to a low of $1.6 million in Q1 2023.
- A 5-year average of $13.2 million and a median of $9.0 million in 2023 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue sank 56.52% — and 2024, when it jumped 1739.56%.
- Tracing INVA's Cost of Revenue over 5 years: stood at $3.7 million in 2022, then plunged by 56.52% to $1.6 million in 2023, then jumped by 1739.56% to $29.4 million in 2024, then soared by 53.14% to $45.1 million in 2025, then tumbled by 65.38% to $15.6 million in 2026.
- The last three Cost of Revenue figures came in at $15.6 million (Q1 2026), $45.1 million (Q3 2025), and $10.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 22.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.35 Mn |
| Jun 30, 2026 | 22.35 Mn |
| Mar 31, 2026 | 15.61 Mn |
| Mar 31, 2026 | 15.61 Mn |
| Sep 30, 2025 | 45.08 Mn |
| Sep 30, 2025 | 45.08 Mn |
| Jun 30, 2025 | 10.59 Mn |
| Jun 30, 2025 | 10.59 Mn |
| Mar 31, 2025 | 8.84 Mn |
| Mar 31, 2025 | 8.84 Mn |
| Sep 30, 2024 | 29.43 Mn |
| Sep 30, 2024 | 29.43 Mn |
| Jun 30, 2024 | 8.47 Mn |
| Jun 30, 2024 | 8.47 Mn |
| Mar 31, 2024 | 10.97 Mn |
| Mar 31, 2024 | 10.97 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 8.98 Mn |
| Jun 30, 2023 | 8.98 Mn |